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Summary Levels of the tumour markers neurone specific enolase (NSE), lactate dehydrogenase (LDH),
chromogranin A (ChrA) and carcinoembryonic antigen (CEA) were measured in serum taken at presentation
and during treatment, remission and relapse from 154 patients who received chemotherapy for small cell lung
cancer at a single centre over a 6 year period. At presentation NSE was the most frequently elevated marker,
being raised in 81% of patients and significantly higher in extensive as opposed to limited disease, as were
LDH and ChrA. The response rate to therapy was best correlated with presentation level of ChrA, being 79%
for those whose levels were within twice the upper limit of normal and 51% above (P<0.01). Multivariate
regression analysis showed NSE, performance status and albumin at presentation to be the best independent
predictors of survival. Patients with NSE below twice the upper limit of normal, Karnofsky performance
status of 80 or above and albumin 35 g 1- or above had a median survival of 15 months with 25% alive at 2
years, whilst those with NSE above twice normal, Karnofsky below 80 and albumin less that 35 g l' had all
died by 8 months. Changes in marker levels during therapy were of low predictive value for outcome although
the finding of rising NSE during chemotherapy after an initial fall correlated with significantly reduced
duration of remission. There was a strong inverse correlation between the NSE level at the time of response
and duration of remission (P<0.0001). Prediction of relapse was most reliable with ChrA, 52% of patients
having rising levels before clinical evidence of disease recurrence.
Despite marked sensitivity to both chemotherapy and radio-
therapy the overwhelming majority of small cell (oat cell)
carcinomas of the bronchus are incurable. Whilst initial treat-
ment results in substantial reduction in the tumour for most
patients, subsequent recurrence with resistance to salvage
therapy is the rule. In a recent analysis (Souhami & Law,
1990) less than 6% of patients were found to have survived 2
years from diagnosis.
The high metabolic rate and neuroectodermal ontogeny of
small cell lung cancers result in the production of a variety of
substances with potential for use as tumour markers. En-
zymes (Carney et al., 1982; Bork et al., 1988), secretory
peptides (O'Connor & Deftos, 1986; Sobol et al., 1986;
North et al., 1988), hormones (Hansen et al., 1980) and cell
surface molecules (Sculier et al., 1985; Jaques et al., 1988)
have all been assayed in the circulation in the hope of
identifying those which might contribute to the management
of patients, either by screening for early diagnosis, defining
prognosis or guiding treatment. To date however none has
proven overwhelmingly superior and the need remains to
examine potential candidates for their applicability in a varie-
ty of patient groups.
This report details the results of an analysis of neurone
specific enolase (NSE), lactate dehydrogenase (LDH), car-
cinoembryonic antigen (CEA) and chromogranin A (ChrA)
levels measured prior to and during treatment of a series of
154 patients receiving chemotherapy at a single centre.
Patients and methods
Between 1984 and 1990 patients presenting with histologi-
cally confirmed small cell lung cancer had blood taken for
the cryopreservation of serum and plasma at - 40C. When
possible, samples were drawn from all patients at presenta-
tion, then before each cycle of chemotherapy and at visits to
outpatients. Patients were told the purpose of collection of
the samples and their consent was obtained prior to phle-
botomy. Aliquots of plasma were centrifuged at 4°C and
frozen down immediately. Serum samples were allowed to
stand for 30 min at room temperature before centrifugation
and freezing.
A complete history and physical examination as well as
determination of their performance status according to the
Karnofsky scale was carried out for all patients before fur-
ther investigations to define the extent of disease. These
routinely included haematology and biochemistry, chest X-
ray, bone marrow biopsy, radionuclide bone scan and liver
ultrasound or computed tomography. In the presence of
neurological symptoms or signs computed tomographic scans
of the brain were performed. Limited disease was defined by
the restriction of tumour to one hemithorax and ipsilateral
supraclavicular lymph nodes (including pleural effusions if
cytologically negative).
Patient characteristics
Of the 154 patients included in the study, 100 (65%) were
male. Their ages at diagnosis ranged from 34 to 77 with a
median of 63 years. Performance status at presentation
ranged from 20 to 100 with a median of 80. Fifty-two (34%)
patients had limited disease and 102 (66%) extensive.
Treatment
The majority of patients (119) received initial treatment with
etoposide given as a single agent in a series of phase II and
phase III studies designed to investigate the optimal dose
schedule for this drug (Slevin et al., 1989). The remaining
patients received either doxorubicin-containing combination
chemotherapy (30 patients) or (in five elderly patients with
extensive disease) mitozantrone as a single agent. Radio-
therapy was not routinely given with chemotherapy, either to
the primary site or prophylactically to the brain.
A complete response was defined as the disappearance of
all evidence of disease for at least 1 month. Partial response
was defined as a 50% or more reduction in the sum of the
products of the perpendicular diameters of measurable les-
ions, or reduction to only minimal radiologic abnormality
where lesions were evaluable but not measurable.
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Follow up
After completion of chemotherapy patients reaching clinical
response were observed without further therapy in the out-
patient clinic. Attendances were monthly initially, with pro-
longation of the interval to 2 monthly after 1 year. Clinical
examination was carried out at each visit with chest X-rays
at least every second visit. Further investigations such as liver
ultrasound or computed tomography were performed as
indicated by symptoms or to assess sites previously known to
be involved.
Exclusions
During the period of the study, 55 patients commenced
chemotherapy for whom no samples were stored, either for
logistic reasons or because they declined phlebotomy. In
patients for whom no pre-treatment sample was available but
for whom sequential samples had been stored these latter
were analysed during remission and relapse.
Tumour marker assays
Serum aliquots for measurement of NSE, LDH, ChrA and
CEA levels were thawed within 4 h before the assays were
performed. NSE was measured in serum using a radioimmu-
noassay (Pharmacia Diagnostics AB, Uppsala). The normal
range is 0-12.5mgl l with a lower detection limit of 2.0
mgl1'. LDH was measured using a kinetic enzyme assay
(Merck, Darmstadt). The normal range is 80-240iul-'.
CEA was measured by immunoradiometric assay (Medgenix
Diagnostics, Brussels). The normal range is 0-3.0mg 1'
with a lower detection limit of 0.14mgl1'. ChrA was
measured by double antibody competitive radioimmunoassay
at the Nichols Institute, San Juan Capistrano, California.
The normal range is 0-50 mg 1' with a lower detection limit
of 1.5mgl"'.
Statistical methods
Survival curves were calculated by the method ofKaplan and
Meier, and the log-rank method used to test differences
between them (Kaplan & Meier, 1958). Multivariate analysis
was carried out using Cox regression (Cox, 1972). The
natural logarithms ofvariables with non-normal distributions
were used in regression analysis to reduce the influence of
widely outlying values. The Mann-Whitney test was used to
compare marker levels in different groups ofpatients and the
prevalence of elevated levels in different groups was com-
pared by contingency tables and calculation ofx2 with Yates'
correction. A level of P<0.05 was taken as significant.
Results
The objective response rate to chemotherapy was 67% with
13 (8%) complete responses and 91 (59%) partial responses.
Table I Marker elevation at presentation
Limited Extensive
disease disease P
Neurone specific enolase
Median (mglI') 20.9 51.5 <0.001
% >12.5mgl-' 77 85 0.41
% >25mgl-' 44 67 0.03
Lactate dehydrogenase
Median (iul-') 168 262 <0.001
% >240 iul-I' 21 54 <0.01
% >480 iul-' 2 17 0.037
Chromagranin A
Median (mg' 1) 49.5 86.5 <0.01
% >50mg ll 50 71 0.028
% >100mgl-' 15 48 <0.001
Carcinoembryonic antigen
Median (mgl') 1.7 3.8 0.09
% >3.0 mgI-' 20 47 0.24
% >6.0mglI' 15 38 0.22
The median duration of remission for patients who res-
ponded to chemotherapy was 6 months and median survival
for the whole group 12 months, with 13% ofpatients alive at
2 years.
Elevation ofmarkers atpresentation
Neurone Specific Enolase was the most commonly elevated
marker, being above 12.5 mg1' in 99 (81%) of 121 patients
for whom a presentation level was measured. The median
level was higher in patients with extensive as compared to
limited disease: 51.5 mg1' and 20.9 mg1' respectively (P<
0.001). However, the proportion of patients in whom the
level was above the upper limit of normal did not differ
significantly between the groups. It was elevated in 66 of 78
(85%) patients with extensive disease compared to 33 of 43
(77%) with limited disease (P = 0.41). Taking a cutoff of
twice the upper limit of normal improved discrimination: 52
(67%) of patients with extensive disease were above 25 mg I` vs 19 (44%) of those with limited (P<0.05). These results
and those for the other markers are shown in Table I.
Lactate dehydrogenase levels were also closely correlated
with anatomical extent of disease, with highly significant
differences in median levels and proportion of patients with
elevated markers between the two stages. Chromogranin A
similarly showed a correlation with stage with the best dis-
crimination at twice the upper limit of normal, whilst Car-
cinoembryonic antigen levels did not.
Correlation between levels for the markers showed
significant associations between NSE and LDH, NSE and
ChrA, and LDH and ChrA (P<0.01 in all cases). CEA
levels did not appear to correlate closely with the other
markers.
Response to chemotherapy andmarker levels atpresentation
A Chromogranin A level at presentation of over twice the
upper limit of normal or an LDH level above normal were
significantly associated with a low response rate. Sixty-four
(79%) of 81 patients with ChrA levels less than 100 mg1-
showed an objective response to treatment, as compared to
23 (51%) of 45 with levels greater than this (P<0.01).
Similarly 57 (81%) of 70 patients with normal LDH res-
ponded as compared to 28 (55%) of 51 with high levels
(P<0.01). NSE and CEA levels at presentation did not
correlate with the response to treatment.
Prediction ofsurvivalpatterns: Univariate analysis
The relationship between potential prognostic variables and
survival was explored initially using log-rank analysis. The
presentation factors analysed were NSE level, LDH level,
performance status, ChrA level, aspartate transaminase level
(AST), stage, serum albumin, alkaline phosphatase level,
serum sodium, treatment protocol entered and CEA level -
given in order of descending significance. Figure 1 shows
survival curves for groups of patients separated according to
the first six of these factors. The results are summarised in
Table II for analyses using a single cut-off point for the
continuous variables. Similar results were obtained if quartile
groups were analysed using the test for trend (data not
shown).
Multivariate analysis ofprognosticfactorsfor survival
Stepwise Cox regression analysis was used to construct a
multivariate model for the 101 patients in whom NSE, LDH,
ChrA, performance status, stage sodium, AST and albumin
were all available. NSE, LDH, ChrA and AST each showed
marked correlation with survival when examined as con-
tinuous variables, with the most powerful association for
NSE. Owing to considerable correlation between these fac-
tors, when NSE was used in the multivarite model the next
significant determinant of survival was performance status,
followed by serum albumin. Table III shows the model762 P.W. JOHNSON et al.
Table H Univariate analysis of prognostic factors for survival (log-rank test)
Median survival % alive
Factor Value (Months) at 2 years P
NSE <25mg'1- 15 27 <0.001
>25 mg 1' 7.5 1
LDH <240 iu I-' 12 23 <0.001
>240iuh-' 5.0 0
Karnofsky 90-100 12.8 28 <0.001
Performance 70-80 10.1 10
status 20-60 3.8 3
Chr A < 100 mg 1- 12.3 20 <0.001
>100mgl-1 5.0 3
AST <40 iu 1-' 10.9 11 <0.001
>40iul-' 4.8 0
Stage Limited 11.4 19 <0.001
Extensive 7.0 8
Albumin >35gl'- 10.0 16 <0.01
<35gl-l 5.0 12
Alkaline phosphatase, sodium, treatment protocol, CEA >0.05
Neurone-specific enolase:
100
CHI = 25.97
P < 0.001
Below 25
ng/ml
80
60
40
N = 51 20
4 5 6
Lactate dehydrogenase:
CHI = 36.56
P < 0.001
Below 240 iu/I
= 70
1 2 3 4 5 6
Time (years)
Performance status:
CHI = 36.67
P < 0.001
Time (years)
100
80
60
40
20
70-80
N = 103
K- 90-100 Nk-N = 44
1 2 3 4 5 6
Time (years)
Aspartate transaminase:
CHI = 17.81
P < 0.001
Below 40 u/I
N = 37
Above 40 u/I
3 4 5 6
CHI = 31.38
P < 0.001
Above ¶06 ng/mI
N = 45
81
1 2 3 4 5 6
Time (years)
Extensive
N = 145
CHI = 15.63
P < 0.001
Limited N = 64
Time (years)
Figure 1 Survival curves drawn according to prognostic factors: Percentage of patients surviving plotted against time from
diagnosis.
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Test for trend: P< 0.001
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Figure 2 Prognostic groups defined according to NSE, performance status and albumin: curves according to number of adverse
features: NSE above 25 mgl-; Performance status below 80; Albumin below 35 g 1'.
derived from the multivariate analysis. The use of NSE,
performance status and albumin to construct a prognostic
model yielded four groups with significantly different survival
patterns (Figure 2). Patients with NSE less than twice the
upper limit of normal, performance status of 80 or over and
albumin 35 g -' or more showed a median survival of 16.2
months with 25% 2 year survival, whilst those with NSE
over twice normal, performance status of 70 or below and
albumin below 35gl-' had a median survival of only 3
months and had all died by 8 months. Patients with one or
two adverse features formed groups of intermediate prog-
nosis.
Changes in marker levels with treatment
Serial samples were analysed for 56 patients during chemo-
therapy for whom at least three specimens were available.
NSE levels fell in all but one patient, regardless of the
response to treatment (Figure 3). However initially elevated
NSE levels were normalised in 36 (84%) of 43 patients
entering remission but only four (40%) of ten in whom the
treatment failed (P= 0.01). LDH levels normalised in 15
(94%) of 16 patients with initial high levels who showed an
objective response to therapy and in three (43%) of seven
who did not (P= 0.03). ChrA appeared more sensitive to
treatment failure with five of six patients in whom the treat-
ment failed showing a rising level, although levels were
elevated in 23 of 39 patients in remission, only 19 of whom
had raised levels at presentation. CEA levels showed no
consistent change according to response. Thus although in
patients with initially raised levels of NSE, LDH and ChrA
the changes correlated with response to treatment, they were
of low predictive power for the outcome when the whole
population was considered.
Table HI Multivariate analysis of prognostic factors for survival
Coefficientl
Standard Standard
Factor Coefficient error error P
Lo& (NSE) 0.4111 0.1072 3.8337 0.0001
Performance - 0.0226 0.0097 - 2.3221 0.02
status
Lo& (Albumin) -2.3539 0.9417 -2.4997 0.01
Patients entering rem on
1 C)
Z t'
Eu- -
Baseine Remission
Patients not entering remission
103 -1
1024
E
LU
U)
z
101.
loo0
Baseline End ofchemotherapy
Figure 3 Changes in Neurone Specific Enolase levels with chem-
otherapy.
100
80
a)
60
40
114,764 P.W. JOHNSON et al.
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a) a1)
a)
C-)
CHI = 3.988
P= 0.046
Steady/falling level
N = 26
Years
Figure 4 Remission duration in patients with rising NSE levels during chemotherapy compared with those with stable or falling
levels.
Too few clinical complete responses were seen to allow
separate analysis of marker levels in remission for those
reaching complete as opposed to partial response. There was
however a highly significant association between the NSE
level at the time of remission and the duration of the remis-
sion (P<0.0001). Similarly a fall of 50% or more in the
NSE level with treatment also correlated with increased
remission duration (P<0.05), as did a fall of 50% or more
in LDH (P<0.01). Changes in ChrA and CEA levels
showed no significant relationship with duration of remis-
sion.
In analysing serial measurements of marker levels it was
evident that in some patients the levels initially fell during
treatment but subsequently rose again despite continued
chemotherapy. That this might be due to outgrowth of a
chemoresistant tumour sub-clone was tested by analysing the
time to disease progression after the end of chemotherapy.
Patients with such rising NSE, LDH or ChrA levels during
chemotherapy had a shorter duration ofremission than those
with steady or falling levels, an association which reached
significance in the case of NSE where the median remission
durations of the two groups were 4 and 7 months respec-
tively (Figure 4).
Changes in marker levels at the time ofrecurrence
Analysis of marker levels between the time of clinical res-
ponse and disease progression showed that ChrA levels rose
prior to clinically-detectable relapse in 16 of 31 (52%)
patients. LDH levels rose in 17 of42 (40%), NSE levels in 17
of 45 (38%) and CEA levels in 12 of 33 (37%). (Table IV).
Two patients had rises in the levels of each marker without
subsequently developing clinical evidence of recurrence dur-
ing follow up.
Table IV Percentages of patients showing rising marker levels (by
10% or more) before, synchronous with and after clinical
recurrence
ChrA LDH NSE CEA
(n =31) (n = 42) (n = 45) (n = 33)
Rise before relapse 52 40 38 37
(Median interval in days) 71 64 35 33
Rise at relapse 13 21 27 18
Rise after relapse 13 19 22 21
No rise 22 20 13 24
Discussion
The treatment of small cell lung cancer remains frustrating in
that very few long-term cures are achieved despite evident
sensitivity to both chemotherapy and radiotherapy. The pos-
sibility of increasing the cure rate by selecting those patients
for whom an intensification of treatment may be worthwhile
is an appealing prospect for a reliable prognostic system.
Conversely the identification of the much larger group of
patients for whom cure is impossible is equally important if
unjustifiable toxicity is to be avoided in their palliative treat-
ment. Whilst the clinical staging system used for small cell
lung cancer certainly has prognostic significance it may be
that this can be refined by the use of tumour markers. A
further potential application of tumour markers is in the
subsequent management of patients receiving treatment: the
extension of therapy for those nearly, but not quite, cured
might be possible were a serological test for the presence of
residual disease available, and an early indicator for immi-
nent relapse would allow prompt 'salvage' treatment to be
started. The present study attempts to define areas where
progress may be made in addressing these issues.
The population of patients studied necessarily represents a
selected sample of those developing small cell lung cancer.
Referral to a specialist centre with a particular interest in the
illness is one means by which this selection has occurred, and
the restriction to those patients well enough to consent to
have samples stored is another. Although the patients within
the study thus represent a group with relatively good prog-
nosis, it is encouraging that the results of the univariate
analyses of other prognostic factors are the same whether or
not those patients excluded from the multivariate analysis are
included. This suggests that the multivariate analysis from
the smaller sample may nonetheless be more widely appli-
cable.
This study has confirmed the previous findings of elevated
NSE levels in the majority of patients with small cell lung
cancer, although in a rather higher proportion than prev-
iously reported, particularly in those with limited disease
(Esscher et al., 1985; Bork et al., 1988; Jorgensen et al.,
1989). That 81% of patients have elevated levels at presenta-
tion suggests that this may be a useful diagnostic test where
the histological or cytological features are in doubt, since less
than one fifth of patients with non-small cell lung cancer
have raised levels (Burghuber et al., 1990). Neurone-specific
enolase levels are higher in patients with extensive disease butTUMOUR MARKERS IN SCLC 765
there is considerable overlap with limited disease. That NSE
does not relate solely to anatomic tumour burden is also
suggested by the finding that the levels initially fell regardless
of the response to chemotherapy. The additional finding of a
shorter remission duration in patients whose levels subse-
quently rose again despite continued treatment may have
considerable significance for the selection of therapy and
should be prospectively tested in larger numbers of patients.
The prognostic significance of NSE level has only been
tested in multivariate analysis in one previous study (Jor-
gensen et al., 1988), whose results are confirmed here.
Neurone-specific enolase is the best single predictor of both
remission duration and overall survival in this series of
patients and although closely correlated with the more widely
used LDH it carries independent power even when the latter
is included in regression analysis. This is of particular
relevance in patients with a relatively good prognosis: of 34
patients with NSE below twice normal and performance
status 80 or more only one had a raised LDH, whilst of 52
patients with normal LDH and performance status of 80 or
more 19 had NSE above twice normal and formed a group
with significantly worse survival (P = 0.012). The neurone-
specific enolase thus contributes additional information in
approximately one third of such patients.
Chromogranin A has particular relevance to the detection
of treatment failure, for which it appears superior to the
other markers examined. The majority of patients for whom
initial chemotherapy failed showed rising ChrA levels during
treatment and 78% of patients had rises at the time of
recurrence. Just over half these pre-dated the clinical diag-
nosis by a median interval of 10 weeks. Although there is a
correlation between ChrA and LDH levels at presentation
and both are predictive of the response rate to chemo-
therapy, the association is lost during treatment as LDH
levels fall in nearly all patients irrespective of the response.
Several previous studies have examined the usefulness of
CEA as a marker for small cell lung cancer, but as in this
case the proportion ofpatients with elevated levels at presen-
tation has generally been reported as less than half (Goslin et
al., 1981; Lokich, 1982; Sculier et al., 1985), limiting its
applicability. The use of CEA as a prognostic factor has
yielded inconclusive results with some studies reporting a
relationship between presentation level and survival (Sculier
et al., 1985; Laberge et al., 1987; Krischke et al., 1988),
although multivariate analyses were not performed and
others found no correlation (Lokich, 1982; Waalkes et al.,
1982; Jaques et at., 1988), a result confirmed in this study.
Studies of serial measurements of CEA have suggested that
these correlate closely with the clinical course (Woo et al.,
1981; Havemann et al., 1985; Shinkai et al., 1986) although
this was not the finding in this study.
Conclusion
This study has confirmed the utility of NSE as a sensitive
marker for small cell lung cancer and demonstrated its pre-
eminent prognostic significance in multivariate analysis for
remission duration and survival. A rising level ofNSE during
treatment following an initial fall is predictive of short remis-
sion duration, suggestive of the emergence of resistance, and
future studies to investigate this further may broaden its
usefulness for directing changes of therapy. LDH has also
been shown to be of prognostic significance although closely
related to NSE, to which it is generally inferior. A raised
LDH does however appear to predict the likelihood of
chemoresistance to some extent, as does raised ChrA. The
sensitivity of ChrA to treatment failure suggests that it may
be of considerable use in monitoring remission, and prospec-
tive studies are now needed to define its predictive power.
This might allow testing of the hypothesis that early salvage
chemotherapy for recurrent disease could improve the out-
look for what is at present a very poor situation. In summary
the combination of NSE as a prognostic factor and monitor
during active treatment and ChrA during remission to detect
early recurrence would appear the ideal at present, although
clearly the development of more effective agents for treat-
ment is a goal to render such considerations redundant.
Without such agents, however, the use of markers may
enable the more rational and effective use of those that are
available.
The authors are pleased to thank Dr H. Rees for histopathological
review and the Department of Radiology for many imaging studies.
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